Study on drug synthesis and activity of sodium olpadronate.
- Published in:
- Journal of Chinese Pharmaceutical Sciences, 2022, v. 31, n. 11, p. 883, doi. 10.5246/jcps.2022.11.075
- By:
- Publication type:
- Article
Works matching IS 10031057 AND DT 2022 AND VI 31 AND IP 11
Results: 7
1
2
Hepatic safety of caspofungin during treatment of fungal diseases in neonates.
- Published in:
- Journal of Chinese Pharmaceutical Sciences, 2022, v. 31, n. 11, p. 877, doi. 10.5246/jcps.2022.11.074
- By:
- Publication type:
- Article
3
Exploration of collaborative drug therapy management mode for elderly patients with chronic diseases.
- Published in:
- Journal of Chinese Pharmaceutical Sciences, 2022, v. 31, n. 11, p. 866, doi. 10.5246/jcps.2022.11.073
- By:
- Publication type:
- Article
4
Efficacy and safety of ACEI plus tanshinone for acute exacerbation of pulmonary heart disease: a meta-analysis.
- Published in:
- Journal of Chinese Pharmaceutical Sciences, 2022, v. 31, n. 11, p. 853, doi. 10.5246/jcps.2022.11.072
- By:
- Publication type:
- Article
5
The alleviating effect of quercetin on carbon tetrachloride-induced liver fibrosis in rats and its underlying mechanism.
- Published in:
- Journal of Chinese Pharmaceutical Sciences, 2022, v. 31, n. 11, p. 840, doi. 10.5246/jcps.2022.11.071
- By:
- Publication type:
- Article
6
Deciphering the latent mechanism of nobiletin in the treatment of metabolic syndrome based on network pharmacology and molecular docking.
- Published in:
- Journal of Chinese Pharmaceutical Sciences, 2022, v. 31, n. 11, p. 803, doi. 10.5246/jcps.2022.11.069
- By:
- Publication type:
- Article
7
Dihydromyricetin improves liver fat deposition in high-fat diet-induced obese mice.
- Published in:
- Journal of Chinese Pharmaceutical Sciences, 2022, v. 31, n. 11, p. 824, doi. 10.5246/jcps.2022.11.070
- By:
- Publication type:
- Article